Drug Trial Radar · NCT06268769
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
322
Actual
Start
Mar 9, 2024
Primary completion
Feb 4, 2026
Study completion Nov 2028
Sponsor
- Lead sponsor
- Edward GeisslerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chiesi Pharmaceuticals GmbH
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.
Conditions
- Immunosuppression
Interventions
Tacrolimus PillDrug
Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Tacrolimus capsuleDrug
Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)Time frame: 12 weeks after kidney transplantation
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Aachen, Department of General, Visceral and Transplant Surgery
Aachen, Germany
Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
Berlin, Germany
Knappschaft Clinic, University Hospital Bochum, Department of Surgery
Bochum, Germany
University Hospital Dresden, Division of Nephrology
Dresden, Germany
University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
Hamburg, Germany
Hannover Medical School, Department of General, Visceral and Transplant Surgery
Hanover, Germany
University Hospital Jena, Internal Medicine III, Nephrology
Jena, Germany
University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
Mainz, Germany
University Hospital Mannheim, Medical Clinic V
Mannheim, Germany
LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
Munich, Germany
University Hospital Münster, Medical Clinic D
Münster, Germany
University Hospital Regensburg, Department of Nephrology
Regensburg, Germany
University Hospital Würzburg, Medical Clinic I, Department of Nephrology
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.